Attached files

file filename
EX-99.2 - EXHIBIT 99.2 - NORTHWEST BIOTHERAPEUTICS INCv330441_ex99-2.htm
EX-99.1 - EXHIBIT 99.1 - NORTHWEST BIOTHERAPEUTICS INCv330441_ex99-1.htm



SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 


 

FORM 8-K

 


 

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934

 


 

Date Of Report (Date Of Earliest Event Reported): December 17, 2012

 


 

NORTHWEST BIOTHERAPEUTICS, INC.
(Exact Name of Registrant as Specified in Its Charter)

 


 

Delaware   0-33393   94-3306718
(State Or Other Jurisdiction Of Incorporation)   (Commission File Number)   (I.R.S. Employer Identification No.)

 

4800 Montgomery Lane, Suite 800, Bethesda, MD 20814
(Address Of Principal Executive Offices) (Zip Code)

 

Registrant’s Telephone Number, Including Area Code (240) 497-9024

 

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 
 
Item 7.01Regulation FD Disclosure.

 

On December 17, 2012, Northwest Biotherapeutics, Inc. (the “Company”) issued a press release announcing that it will be ringing The NASDAQ Stock Market Opening Bell on Tuesday, December 18, 2012. A copy of the press release is included as Exhibit 99.1 to this Current Report on Form 8-K.

 

In addition, on December 17, 2012, the Company sent a letter to its stockholders along with a copy of the press release. A copy of the letter to stockholders is included as Exhibit 99.2 to this Current Report on Form 8-K.

 

Item 9.01Financial Statements and Exhibits

 

Exhibit No.Description

 

99.1Press Release of Northwest Biotherapeutics, Inc. dated December 17, 2012.

 

99.2Letter to Stockholders of Northwest Biotherapeutics, Inc. dated December 17, 2012.

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  NORTHWEST BIOTHERAPEUTICS, INC
       
Dated: December 17, 2012 By: /s/ Linda Powers  
    Name:  Linda Powers  
    Title: Chief Executive Officer and Chairman